Scott Gettinger, MD
Professor of Internal Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Thoracic Medical Oncology
Contact Info
About
Copy Link
Titles
Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Biography
Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy and targeted therapy for non-small cell lung cancer. He currently leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary translational research interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Center for Thoracic Cancers
- Developmental Therapeutics
- Internal Medicine
- Medical Oncology and Hematology
- SPORE in Lung Cancer
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
- Yale Ventures
Education & Training
- Fellow
- Beth Israel Medical Center, NY (2005)
- Resident
- Beth Israel Medical Center, NY (2002)
- Residency
- Beth Israel Medical Center (2001)
- MD
- Brooklyn College (1999)
- BS
- Trinity College (1991)
Research
Copy Link
Overview
Medical Research Interests
Carcinoma, Non-Small-Cell Lung; Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Immunotherapy; Lung; Medical Oncology; Thoracic Neoplasms; Translational Research, Biomedical
ORCID
0000-0003-0886-6880
Research at a Glance
Yale Co-Authors
Frequent collaborators of Scott Gettinger's published research.
Publications Timeline
A big-picture view of Scott Gettinger's research output by year.
Research Interests
Research topics Scott Gettinger is interested in exploring.
Roy S. Herbst, MD, PhD
David Rimm, MD, PhD
Harriet Kluger, MD
Anna Wurtz
Kurt Schalper, MD, PhD
Sarah Goldberg, MD, MPH
329Publications
57,908Citations
Carcinoma, Non-Small-Cell Lung
Immunotherapy
Lung
Medical Oncology
Thoracic Neoplasms
Translational Research, Biomedical
Publications
2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Bazhenova L, Hodgson J, Camidge D, Langer C, Huber R, Kim D, Reckamp K, Ahn M, Tan D, Patel J, Vincent S, Li C, Humphries M, Zhang P, Rivera V, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clinical Lung Cancer 2025, 26: e503-e513.e11. PMID: 40582920, DOI: 10.1016/j.cllc.2025.05.016.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObjective response rateProgression-free survivalMedian progression-free survivalALK-positive NSCLCCirculating tumor DNAALK mutationsALK fusionsMutation statusALK-positive non-small-cell lung cancerNon-small-cell lung cancerPlasma circulating tumor DNAActivity of brigatinibBaseline tumor samplesSecondary ALK mutationsMechanisms of resistanceALK alterationsALK amplificationALK inhibitorsPhase 1/2Preclinical activityTumor DNABrigatinibTumor samplesLung cancerTumor tissuesClinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Nie Y, Wurtz A, Li F, Schalper K, Duffield E, Rowen E, Gerrish H, Chiang A, Goldberg S, Wilson F, Kim S, Grant M, Sabbath K, Talsania A, Lasala J, Russo A, Politi K, Herbst R, Gettinger S. Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43: 8544-8544. DOI: 10.1200/jco.2025.43.16_suppl.8544.Peer-Reviewed Original ResearchConceptsMetastatic non-small cell lung cancerNon-small cell lung cancerMonocyte-to-lymphocyte ratioAbsolute lymphocyte countPre-treatment absolute lymphocyte countResponse to immunotherapyCell lung cancerExceptional respondersLiver metastasesImmunotherapy responseAdvanced non-small cell lung cancerLung cancerTumor PD-L1 expressionPresence of brain metastasesInfluence immunotherapy responsivenessPD-L1 expressionSubsets of patientsTumor microenvironment analysisYale Cancer CenterTumor tissue analysisIRB-approved protocolLong-term survivalConcurrent chemotherapyBrain metastasesClinicopathological predictorsPhase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
Creelan B, Gettinger S, Chesney J, Sukari A, He K, Lee S, Garon E, Nieva J, Martin-Liberal J, Rodriguez Moreno J, Zugazagoitia J, Doger de Spéville B, Josephs D, Gibney G, Thomas S, Samhouri Y, Samakoglu S, Feng M, Finckenstein F, Schoenfeld A. Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8659.Peer-Reviewed Original ResearchCitationsConceptsMetastatic non-small cell lung cancerNon-small cell lung cancerTumor-infiltrating lymphocytesCell lung cancerStandard-of-careIL-2Advanced non-small cell lung cancerLung cancerIn vivo T-cell persistencePhase 2 open-label studyECOG performance status 0Treatment-emergent adverse eventsResponse rateFrontline maintenance therapySymptomatic brain metastasesComplete response rateDisease control rateDose of pembrolizumabPerformance status 0Platinum-doublet chemotherapyT cell persistenceCell transfer therapyCirculating tumor DNAEGFR wild-typeEffective targeted therapies
2024
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Kong X, Tricoli J, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, Flaherty K. Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology 2024, 8: e2300725. PMID: 38986051, DOI: 10.1200/po.23.00725.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsProgression-free survivalTyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsNCI-MATCHLung cancerGlioblastoma multiformeOverall survivalAdvanced non-small cell lung cancerNational Cancer Institute-Molecular AnalysisNon-small cell lung cancerEnd pointsTumor genomic testingTrial primary end pointPhase 2 trialPhase II trialSecondary end pointsPrimary end pointCell lung cancerCohort of patientsMedian OSStable diseaseAdenosquamous carcinomaProtocol therapyPartial responseArm ALifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Schoenfeld A, Lee S, de Speville B, Gettinger S, Hafliger S, Sukari A, Papa S, Rodríguez-Moreno J, Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller E, Gontcharova V, He K. Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery 2024, 14: 1389-1402. PMID: 38563600, PMCID: PMC11294887, DOI: 10.1158/2159-8290.cd-23-1334.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetastatic non-small cell lung cancerAdverse eventsResistance to immune checkpoint inhibitorsPD-L1-negative tumorsPhase 2 multicenter studyLow tumor mutational burdenTreatment-emergent adverse eventsNon-small cell lung cancerTime of data cutoffRefractory to prior therapyPD-L1-negativeImmune checkpoint inhibitorsResistance to immunotherapyTumor mutational burdenCell lung cancerMultiple organ failurePotential treatment optionCheckpoint inhibitorsPrior therapyData cutoffPatient diedSystemic therapyMutational burdenSTK11 mutationsCardiac failureASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Hu B, Wiesehöfer M, de Miguel F, Liu Z, Chan L, Choi J, Melnick M, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen D, Politi K. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research 2024, 84: 1303-1319. PMID: 38359163, PMCID: PMC11142404, DOI: 10.1158/0008-5472.can-23-0438.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTyrosine kinase inhibitorsPatient-derived xenograftsEGFR mutant lung cancerMutant lung cancerPre-treatment tumorsResidual diseaseDrug toleranceLung cancerResidual tumor cells in vivoEGFR mutant lung adenocarcinomaTyrosine kinase inhibitor osimertinibEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitor treatmentTumor cells in vivoMutant lung adenocarcinomaMaximal tumor regressionTranscription factor Ascl1Drug-tolerant cellsTime of maximal responseEvidence of cellsCells in vivoOsimertinib treatmentTumor regressionSingle cell transcriptional profilingTumor cellsMulti-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, Manyam G, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli M, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray J, Herbst R, Wistuba I, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee J, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research 2024, 30: 1655-1668. PMID: 38277235, PMCID: PMC11016892, DOI: 10.1158/1078-0432.ccr-23-0251.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChromosome copy-number variationsOverall survivalMultiplex immunofluorescenceMulti-omics analysisAssociated with superior progression-free survivalNCounter PanCancer Immune Profiling PanelSquamous cell lung cancer patientsSuperior progression-free survivalTreated with nivolumab monotherapyAssociated with worse overall survivalNon-small cell carcinomaAssociated with worse survivalCell lung cancer patientsCold immune microenvironmentProgression-free survivalImmune Profiling PanelRegulatory T cellsPhase III trialsResponse to ICIImmune cell infiltrationHigher immune scoresImmune cell densityLung cancer patientsWhole-exome sequencingImmune gene expression profiles
2023
MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC
Gettinger S, Goldberg S, Chiang A, Wilson F, Kim S, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Jackson R, Pope J, Myint H, Langermann S, Cheng W, Rimm D, Chen L, Herbst R. MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal Of Thoracic Oncology 2023, 18: s155. DOI: 10.1016/j.jtho.2023.09.224.Peer-Reviewed Original ResearchCitationsConceptsCo-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genesMesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, Bharat A, Bruno D, Chang J, Chirieac L, DeCamp M, Dilling T, Dowell J, Durm G, Gettinger S, Grotz T, Gubens M, Hegde A, Lackner R, Lanuti M, Lin J, Loo B, Lovly C, Maldonado F, Massarelli E, Morgensztern D, Mullikin T, Ng T, Otterson G, Patel S, Patil T, Polanco P, Riely G, Riess J, Shapiro T, Singh A, Tam A, Tanvetyanon T, Yanagawa J, Yang S, Yau E, Gregory K, Hughes M. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 961-979. PMID: 37673108, DOI: 10.6004/jnccn.2023.0045.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
Clinical Trials
Current Trials
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
HIC ID2000028827RoleSub InvestigatorPrimary Completion Date12/15/2024Recruiting ParticipantsLUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
HIC ID2000025282RoleSub InvestigatorPrimary Completion Date01/28/2029Recruiting ParticipantsDetermining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
HIC ID1603017333RolePrincipal InvestigatorPrimary Completion Date06/20/2026Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Clinical Care
Copy Link
Overview
Scott Gettinger, MD, is a medical oncologist who specializes in lung cancer treatment and research.
He says the best part of his job is the ability to provide the latest advances in treatment to his patients, many of whom have complicated cases and require care from multiple specialists.
Dr. Gettinger leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies for non-small cell lung cancer.
“Treatment for lung cancer is constantly evolving and new treatments are available to target specific tumors,” he says. “There is always something we can offer that will help.”
Clinical Specialties
Thoracic Oncology; Medical Oncology
Fact Sheets
Radiofrequency Ablation (RFA)
Learn More on Yale MedicineMesothelioma
Learn More on Yale MedicineNon-Small Cell Lung Cancer
Learn More on Yale MedicineBrachytherapy
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- November 18, 2025
Progress and Hope: Sharing the Latest Advances in Lung Cancer Care
- November 12, 2025
Twenty-Seven YSM Faculty Members Recognized for Highly Cited Research
- May 30, 2025Source: Yale Medicine
How Smilow Doctors Are Saving My Life: A Cancer Survivor’s Story
- November 14, 2024
Understanding Lung Cancer: A Conference to Raise Awareness and Offer Hope to Those Impacted by Lung Cancer
Get In Touch
Copy Link
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.